Lafayette Investments - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 101 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.

Quarter-by-quarter ownership
Lafayette Investments ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$15,340
-16.3%
13,0000.0%0.00%
-20.0%
Q2 2023$18,330
-6.0%
13,0000.0%0.01%0.0%
Q1 2023$19,500
+28.2%
13,0000.0%0.01%
+25.0%
Q4 2022$15,210
+1.4%
13,0000.0%0.00%
-20.0%
Q3 2022$15,000
-28.6%
13,0000.0%0.01%
-16.7%
Q2 2022$21,000
+5.0%
13,0000.0%0.01%
+20.0%
Q1 2022$20,000
-37.5%
13,0000.0%0.01%
-37.5%
Q4 2021$32,000
-3.0%
13,0000.0%0.01%
-11.1%
Q3 2021$33,000
-10.8%
13,0000.0%0.01%
-10.0%
Q2 2021$37,000
+19.4%
13,0000.0%0.01%0.0%
Q1 2021$31,000
+72.2%
13,000
+30.0%
0.01%
+66.7%
Q4 2020$18,00010,0000.01%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders